Program
pudafensine
Also written as “Pudafensine”, “IP2015” and “IP2015, dose 1”.
Its studies are mostly in Vulvodynia · Pain, led by Initiator Pharma.
Furthest: phase 2, since Jan 21, 20263 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Initiator Pharma | 31 open or running | phase 2since Jan 21, 2026 | Nov 20, 2021 | Dec 31, 2026phase 2 · NCT07391241 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2021First study: phase 1 study in PainFirst studyNCT05181852 · 24 enrolled
- Dec 20, 2022Phase 1 study in BioavailabilityNCT05728671 · 12 enrolled
- Jan 21, 2026Phase 2 study in VulvodyniaPhase 2 reachedNCT07391241 · 24 enrolled · United Kingdom
Ahead
- Dec 31, 2026Primary completion: phase 2 study in VulvodyniaNCT07391241
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07391241Vulvodynia · United Kingdom | 2 | Active, not recruiting | Dec 31, 2026 | 24 |
| NCT05728671Bioavailability | 1 | UNKNOWN | May 16, 2023 | 12 |
| NCT05181852Pain | 1 | UNKNOWN | May 30, 2022 | 24 |
How it is read
Names in the registry
- “Pudafensine”, 1 entry
- “IP2015”, 1 entry
- “IP2015, dose 1”, 1 entry
- “IP2015, dose 2”, 1 entry
Conditions, from the studies’ own filings
- Vulvodynia, 1 study
- Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.